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Abstract
Echo decorrelation imaging, a pulse–echo method that maps heat-induced changes in
ultrasound echoes, was investigated for in vivo monitoring of thermal ablation in a liver
cancer model. In open surgical procedures, rabbit liver with implanted VX2 tumor were im-
aged by image-ablate arrays and treated with bulk ultrasound (unfocused) ablation (N=10)
or high-intensity focused ultrasound (HIFU) (N=13). Echo decorrelation and integrated
backscatter (IBS) images were formed from pulse-echo images recorded during rest periods
following each sonication pulse. Echo decorrelation images were corrected for motion– and
noise–induced artifacts using measured echo decorrelation from corresponding sham trials.
Sectioned ablated tissue was vitally stained with triphenyl tetrazolium chloride (TTC) and
binary images were constructed based on local TTC staining. Analysis was performed for
the focused exposures, unfocused exposures and for all exposures combined.
Motion correction significantly reduced echo decorrelation in non-ablated liver regions.
The reduction was significant in non–ablated VX2 tumor regions for focused exposures and
all exposures combined. The reduction was not significant in ablated VX2 tumor regions
for unfocused exposures. Echo decorrelation reduction was marginally significant in ablated
regions for focused and unfocused exposures and was significant for all exposures combined.
In unpaired comparisons, echo decorrelation was significantly greater in ablated than in
non–ablated liver regions but was not significantly greater in ablated than in non–ablated
VX2 tumor. IBS was significantly greater in ablated than in non–ablated liver except for
unfocused exposures. IBS was not significantly greater in ablated than in non–ablated VX2
regions. In paired comparisons, similar results were seen in comparison to the unpaired
comparison; however, echo decorrelation and IBS were significantly greater in ablated than in
non–ablated VX2 tumor for all exposures combined. Additionally, IBS was not significantly
greater in ablated than in non–ablated liver for unfocused exposures.
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Prediction of ablation by echo decorrelation and IBS imaging was assessed using receiver
operating characteristic (ROC) curves. Areas under the ROC curve (AUC) were significantly
greater than chance for ablated liver prediction by corrected echo decorrelation and IBS. Echo
decorrelation did not predict ablated VX2 tumor significantly better than chance for focused
exposures. IBS did not predict ablated VX2 tumor better than chance for focused exposures
and unfocused exposures. Corrected echo decorrelation predicted ablated liver significantly
better than IBS for the focused exposures and all exposures combined. AUC differences
between corrected echo decorrelation and IBS were not significant for all exposure groups
in ablated VX2 tumor, for which echo decorrelation was marginally higher. At the optimal
threshold, defined as the threshold corresponding to the point nearest to the top left–hand
corner of the ROC plot, echo decorrelation had a better sensitivity than specificity for the
focused and unfocused exposures in normal liver and VX2 tumor.
To assess tissue motion effects due to large inter–frame times, echo decorrelation and
IBS was computed for inter–frame times up to 847.5 ms. Uncorrected and corrected echo
decorrelation prediction performance was marginally affected by large inter-frame times;
however, corrected decorrelation was less affected. IBS prediction performance was nearly
constant by comparison for large inter-frame times. Over the range of inter–frame times
investigated, IBS predicted overall better than echo decorrelation for the unfocused group
while echo decorrelation predicted overall better than IBS for the focused group.
These results indicate echo decorrelation imaging is a successful predictor of local abla-
tion, with potential for real–time ultrasound system implementation and successful clinical
translation. For most cases, echo decorrelation predicted ablated liver better than IBS and
predicted ablated VX2 tumor marginally better than IBS. Tissue motion effects were shown
to have little effect on echo decorrelation’s ablation prediction performance; however, focused
ablation prediction performance could potentially be enhanced by improving pulse–echo im-
age resolution. Additionally, enhancement of prediction performance could be achieved by
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leveraging three–dimensional volume ultrasound imaging systems, which inherently have
slower frame rates, as echo decorrelation’s performance was marginally affected by tissue
motion. These results suggest that echo decorrelation imaging merits further investigation
and has potential to improve real–time monitoring during HIFU thermal ablation and bulk
ultrasound thermal ablation.
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Chapter I
Introduction
1.1 Background and significance
1.1.1 Clinical significance
An estimated 35,660 new cases of liver cancer in the United States are expected in 2015
(Siegel et al., 2015). Hepatocellular carcinoma (HCC) will make up approximately 75% of
these cases (Siegel et al., 2015). Of these new cases, 42% are expected to be diagnosed at
an early stage, for which 5–year survival is 30% (Siegel et al., 2015). Approximately 80%
of these patients will not be candidates for surgical resection or transplantation (Petrowsky
et al., 2008).
HCC is a primary tumor of the liver that usually develops in the setting of chronic liver
disease, particularly in patients with chronic hepatitis B and C, chronic alcohol consumption,
NASH/NAFL (nonalcoholic fatty liver/nonalcoholic steatohepatitis), and Aflatoxin B1 or
other mycotoxins (Bruix et al., 2005). Patients who develop HCC usually have no symptoms
other than those related to their chronic liver disease (Bruix et al., 2005). Liver metastases
(i.e., secondary tumors of the liver) are also a prevalent form of liver cancer and commonly
originate from tumor sites in the breast, lung, and colon (Aubry et al., 2013).
The following sections will discuss treatment options and improvements for HCC, as other
primary cancers of the liver [e.g., cholangiocarcinoma and bile duct cancer (Bruix et al.,
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2005)] and secondary cancers of the liver may potentially benefit from similar treatments
(e.g., thermal ablation).
1.1.2 Current treatment approaches
Resection, liver transplantation, and local nonsurgical therapies are options for early
stage patients [i.e., patients who have fewer than 3 tumors smaller than 3 cm in diameter
(Bruix et al., 2005)]. Surgeons can sometimes remove the tumor (i.e., resection or transplant);
however, if the patient cannot undergo removal (e.g., if there are associated diseases), thermal
ablation may be deployed (Bruix et al., 2005). This approach may also be used as an adjuvant
therapy for transplant candidates to control tumor growth with the aim to extend the time to
find a donor liver (Bruix et al., 2005). The aim of thermal ablation is to achieve malignant
tumor death by delivering heat without damaging adjacent vital structures (Bruix et al.,
2005). An ablative margin ≥5 mm around the entire tumor is often used to eliminate
satellite foci of the disease and to overcome lesion boundary uncertainty (Nishikawa et al.,
2013). A thermal dose can be determined using the empirical equation:
EM43 =
∑
RT (r)−43∆t/60. (1.1)
where ∆t is the time step in seconds, R = 2 for T ≥ 43 ◦C, and R = 4 for T < 43 ◦C
(Sapareto et al., 1984). Thermal dose is the length in minutes of an equivalent treatment at
43 ◦C. Figure 1.1 indicates thermal dose thresholds for treated (EM43 = 200 min) and ablated
tissue (EM43 = 10
7 min) (Mast et al., 2005). In one second, the treated threshold is achieved
at 56 ◦C and the ablated threshold is achieved at 72 ◦C. In 60 minutes, the treated threshold
is achieved at 45 ◦C and the ablated threshold is achieved at 60 ◦C. These thermal dose
thresholds are consistent with empirical tissue viability studies (Karunakaran et al., 2012).
The typical cell–death pathway undergone by thermally ablated cells is coagulative necrosis
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Figure 1.1: Local thermal dose is a function of temperature and treatment duration. The
white region indicates healthy tissue, the red region indicates treated tissue (EM43 = 200
min.) and the purple region indicates ablated tissue (EM43 = 10
7 min.) (Sapareto et al.,
1984; Mast et al., 2005; Karunakaran et al., 2012)
.
(Goldberg, 2001). Thermal ablation approaches aim to achieve and maintain temperatures
between 50–100 ◦C as temperatures greater than 100 ◦C result in poor therapy delivery due
to processes including tissue boiling, vaporization, and carbonization (Goldberg, 2001).
1.1.2.1 Radiofrequency ablation
Radiofrequency ablation (RFA) is the standard minimally invasive liver cancer treatment
approach that uses radiofrequency (< 1 MHz) energy to achieve cytotoxic effects (Goldberg,
2001; Nishikawa et al., 2013; Li et al., 2014). RFA is sometimes used in tandem with transar-
terial chemoembolizatoin (TACE) to reduce perfusion effects which can lead to incomplete
thermal lesioning, resulting in tumor recurrence (Bruix et al., 2005; Li et al., 2014). There is a
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wide spectrum of RFA technologies including monopolar and bipolar electrodes deployed for
liver cancer thermal ablation (Goldberg, 2001). Monopolar electrodes are capable of achiev-
ing spheroidal thermal lesions up to 1.6 cm diameter in approximately 6 minutes (Goldberg,
2001). In monopolar mode, a surface grounding pad completes the electric circuit (Brace
et al., 2009). In bipolar mode, grounding electrodes replace the grounding pad (Brace et al.,
2009; Li et al., 2014). In bipolar configurations, additional heating is achieved at the ground-
ing electrode site resulting in larger lesion long–axis dimensions (e.g., 4.0 cm) but smaller
short–axis dimensions (e.g, 1.4 cm) (Goldberg, 2001). Monopolar configurations are more
frequently deployed (Brace et al., 2009). To achieve larger ablation volumes, multiprobe,
cluster and internally–cooled electrodes have been developed (Goldberg, 2001). Pereira et al.
(2004) observed larger lesioning for internally cooled cluster devices. More spherical and re-
producible lesions were obtained with multiprobe arrays (Pereira et al., 2004). Pereira et al.
(2004) suggested that the reproducibility seen for the multiprobe arrays might suggest im-
proved lesion dimension predictability. Typical RFA tip temperatures range between 70 and
90 ◦C (Goldberg, 2001).
1.1.2.2 Microwave ablation
Microwave ablation is a minimally invasive hyperthermic approach that leverages mi-
crowave radiation (900 to 2450 MHz) to achieve cytotoxic effects (Simon et al., 2005). The
use of microwave ablation for liver tumors has increased and demonstrated equivalent clinical
efficacy compared to radiofrequency ablation (RFA) (Li et al., 2014). In principle, the ben-
efits of microwave ablation in comparison to RFA include: larger ablation volumes, faster
ablation times, and less susceptibility to perfusion effects. These benefits are due to the
faster heating rates and improved power vs. heating linearity (Brace et al., 2009; Li et al.,
2014). Microwave ablation systems can be much simpler as they do not require grounding
pads like RFA (Simon et al., 2005; Li et al., 2014).
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1.1.2.3 Ultrasound ablation
High–intensity focused ultrasound (HIFU) is a thermal ablation approach which enables
non–invasive transcutaneous treatment (Maruyama et al., 2008). Ultrasound is focused
to a specified treatment volume and the acoustic energy is converted into heat resulting
in thermal–induced necrosis in the focal area with less damage to the surrounding tissue
(Kennedy et al., 2003). The temperature at the focus can rise rapidly above 80 ◦C (Kennedy
et al., 2003). Transcutaneous HIFU approaches also avoid needle track seeding (Aubry et al.,
2013). Oncological HIFU applications approved outside the United States are for bone metas-
tases, liver tumors, pancreatic tumors, prostate cancer, kidney tumors, and breast cancer
[Figure 1.2, (Focused Ultrasound Foundation, 2015)]. FDA approved HIFU applications are
for bone metastases and uterine fibroids (Focused Ultrasound Foundation, 2015). However,
shadowing effects of the ribs, breathing motion, and relatively long treatment times (i.e., 1
hour treatment for a superficial 2 cm tumor) are current barriers to clinical adoption (Aubry
et al., 2013; Kennedy et al., 2003). Initial studies have investigated the safety and efficacy
of HIFU and demonstrated its potential as a local ablative approach (Li et al., 2014).
Bulk ultrasound ablation utilizing interstitial probes or catheter–based devices with cylin-
drically omnidirectional (Diederich et al., 1999), planar (Mast et al., 2005), and weakly
focused (Lafon et al., 2002) transducer configurations have also been developed for tumor
ablation. Bulk ultrasound approaches are capable of ablating larger tissue volumes in com-
parison to HIFU within treatment durations similar to RFA (Makin et al., 2005). However,
this approach is sensitive to perfusion heat sink effects, increasing the risk of incomplete
treatment (Mast et al., 2005). Both HIFU and bulk ultrasound approaches offer improved
spatial selectivity and monitoring in comparison to RFA and microwave ablation (Makin
et al., 2005). This treatment enhancement is achieved by image–ablate or dual–mode ar-
rangements which allow coplanar imaging and ablation (Makin et al., 2005).
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Figure 1.2: The number of clinical applications of HIFU being researched, developed, and
commercialized is growing and indicates HIFU’s importance in disease treatment (Focused
Ultrasound Foundation, 2015).
1.1.3 Clinical needs: thermal ablation monitoring
Mulier et al. (2005) reported local tumor recurrence rates between 2% and 60% for 5,224
RFA procedures performed worldwide between 1990 and 2004. Analysis by Mulier et al.
(2005) indicated larger tumor size and increased heat sink effects (i.e., perfusion) as factors
associated with higher local recurrence rates.
Radiofrequency ablation (RFA) and similar approaches (i.e., HIFU and bulk ultrasound
ablation) would be improved if used concurrently with a suitable real time monitoring method
allowing local heat–induced cell death visualization (Li et al., 2014). Tissue temperature
effects can be monitored by magnetic resonance thermometry; however, these clinical ex-
tracorporeal systems [e.g., ExAblate, InSightec Inc., Tirat Carmel, Israel (Kennedy et al.,
2003)] can be costly and cumbersome (Napoli et al., 2013). In China, a clinical extracorpo-
real ultrasound–guided focused ultrasound (USgFUS) system has demonstrated liver tumor
treatment efficacy and safety [(Wu et al., 2009), Chongqing HAIFU, Technology Company,
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Chongqing, P.R., China]. Other USgFUS systems are the Sonablate (Focal Surgery, Milpi-
tas, CA, US) and the Ablatherm (Technomed International, Lyon, France) which are used
to treat prostate cancer (Kennedy et al., 2003). Both the Sonablate and Ablatherm systems
measure echo energy (e.g., integrated backscatter), possibly due to acoustic cavitation, to
provide treatment feedback (Chen, W. H.; ter Haar et al., 2007). Inconsistent echogenicity
changes (Mast et al., 2008) or pulse–echo signal decorrelation (Cespedes et al., 1997) can
render current ultrasound monitoring approaches, including conventional B–mode (bright-
ness mode) imaging (Maruyama et al., 2008), echo energy–based methods [e.g., attenuation
and integrated backscatter (Zhang et al., 2009)], and cross–correlation–based methods [e.g.,
echo strain (Liu et al., 2010) and elastography (Kolokythas et al., 2008) imaging], unreliable
or limited in application.
1.1.4 Ultrasound echo decorrelation imaging
Ultrasound echo decorrelation, a pulse–echo method that maps heat–induced changes in
ultrasound echoes over millisecond time scales, shows promise for real time radiofrequency
and ultrasound thermal ablation guidance and monitoring (Mast et al., 2008; Subramanian
et al., 2014; Fosnight et al., 2014). However, echo decorrelation’s ability to predict the desired
clinical end effect (i.e., death of malignant tumor tissue) in a living subject, where motion
could limit echo decorrelation’s performance, has not been investigated. Tissue structural
changes, pulse–echo strain, vaporization and dissolution of gas as a result of thermal–induced
coagulative necrosis could cause echo decorrelation during thermal ablation (Hooi et al.,
2015). Additionally, acoustic cavitation could cause echo decorrelation during ultrasound
thermal ablation.
Subramanian et al. (2014) investigated echo decorrelation’s ability to predict in vivo bulk
ultrasound ablation of VX2 tumor and surrounding liver tissue and prediction performance of
in vivo RFA of porcine liver. However, poor resolution pulse–echo images could not confirm
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a direct link between echo decorrelation and ultrasound ablated VX2 tumor. The ability of
echo decorrelation imaging to predict in vivo HIFU ablation was also not investigated.
Subramanian et al. (2014) reduced motion–induced artifacts using motion gating; how-
ever, a more effective motion compensation method has employed a theory separating decor-
relation caused by motion, electronic noise, and heat–induced tissue changes, allowing com-
pensation for estimated or measured artifactual decorrelation (Hooi et al., 2015). This
compensation method was shown to allow accurate reconstruction of scattering medium de-
coherence in image simulations and to substantially reduce motion–induced decorrelation
artifacts during in vivo RFA (Hooi et al., 2015).
1.1.4.1 Theory
Corrected echo decorrelation and integrated backscatter images (IBS) were previously
described by Hooi et al. (2015). Briefly, local echo decorrelation per unit time is defined as
∆local(y, z, t) = 2
β2 − |R01(y, z, t)|2
τ [β2(y, z, t) + β(t)2]
, (1.2)
where y is the azimuthal (array) coordinate, z is the range (depth) coordinate, and τ is the
inter–frame time in milliseconds. R01 is the position–dependent, zero–lag, windowed spatial
cross–correlation between two sequential complex image frames I(y, z, t) and I(y, z, t + τ)
separated in time by τ :
R01(y, z) =
∫∫
w(y − y′, z − z′)I(y, z, t)∗I(y, z, t+ τ)dy′dz′
= 〈|I(y, z, t)∗I(y, z, t+ τ)|〉.
(1.3)
The star indicates complex conjugation and the angle brackets denote a convolution with
the window function. The window function w(y, z), is a two–dimensional isotropic spatial
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Gaussian filter with width parameter σ:
w(y, z) = e
−
y2 + z2
2σ2 . (1.4)
An integrated backscatter term β(y, z, t) is then defined as:
β(y, z, t) =
√
R00(y, z, t)R11(y, z, t) (1.5)
and β(t) is the spatial average of the integrated backscatter term. R00 and R11 are the
corresponding zero–lag image autocorrelations:
R00(y, z) = 〈|I(y, z, t)|2〉 and R11(y, z) = 〈|I(y, z, t+ τ)|2〉. (1.6)
As echo decorrelation varies stochastically during ablation, temporal averaging is used
to provide a better estimate of local tissue changes. The temporal maximum of the aver-
aged ∆local at each tissue position is referred to as the cumulative echo decorrelation and is
hypothesized to predict local heat–induced cell death during ablation.
Estimates of artifactual cumulative echo decorrelation obtained from corresponding sham
trials denoted ∆sham are used to construct corrected cumulative echo decorrelation, denoted
∆corrected(y, z, t), from uncorrected cumulative echo decorrelation denoted ∆uncorrected using
the equation (Hooi et al., 2015):
∆corrected(y, z, t) =
∆uncorrected −∆sham
1−∆sham . (1.7)
Relative integrated backscatter (IBS) images are defined as the decibel–scaled ratio be-
tween β(y, z, t) during ablation and the cumulative integrated backscatter βsham(y, z) mea-
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sured for the corresponding sham trial:
IBS(y, z, t) = 10 · log10
(
β(y, z, t)
βsham(y, z)
)
, (1.8)
where β is the integrated backscatter function defined by Equation (1.5). The cumulative
relative integrated backscatter map is the temporal maximum of IBS(y, z, t).
1.1.4.2 Preliminary in vitro ultrasound ablation results
Preliminary bulk ultrasound and HIFU thermal ablation experiments using in vitro
bovine liver (Fosnight et al., 2014) deploying noise correction (Hooi et al., 2015) showed
significant ablation prediction by echo decorrelation.
Ablation and imaging were performed using custom 64 element, 5×24 mm2 linear image–
ablate arrays with >40% pulse–echo fractional bandwidth for imaging and >40 W available
acoustic power for therapy, controlled by the Iris 2 ultrasound imaging and therapy system
[Ardent Sound Mesa, AZ, USA; Barthe et al. (2004)].
For these in vitro experiments, pulse–echo images were acquired for both focused ul-
trasound ablation (N=21, 1 s sonications, 17% duty factor, 6 sonication pulses, 284–769
W/cm2 in situ spatial-peak, temporal-peak intensity [Isptp], electronically focused 10 mm
into the tissue) and bulk ultrasound ablation (N=12, 7.5 s sonications, 60% duty factor, 6
sonication pulses, 50.9–101.8 W/cm2 in situ [Isptp], unfocused aperture). The beamformed,
radiofrequency echo signals were captured at 118 frames per second during 5.0 s rest peri-
ods for both ablation trials and matching sham trials, beginning 1.1 s after each sonication
pulse, using a 14–bit, PC-based A/D converter at 33.3 MHz (CompuScope CS 14200, Gage
Applied Technologies, Montreal, QC, Canada). Echo decorrelation and IBS images were
computed using Equations 1.2–1.6 and a temporal running average was used to provide a
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lower-variance estimate of local tissue changes (Fosnight et al., 2014):
∆uncorrected(y, z, t) = (1− )∆uncorrected(y, z, t− τ) + ∆uncorrected(y, z, t), (1.9)
where the averaging parameter  = 0.05. The temporal maximum of the running-average
echo decorrelation and IBS at each tissue location are referred to as the cumulative echo
decorrelation and IBS images. To remove artifactual decorrelation caused by electronic
noise and tissue or array motion, Equation 1.7 was used.
Tissue samples were frozen at −80 ◦C, sectioned, vitally stained, imaged, and semi-
automatically segmented for receiver operating characteristic (ROC) analysis. ROC curves
were constructed and the area underneath the curve (AUC) computed to assess prediction
performance for echo decorrelation and IBS. Logarithmically scaled echo decorrelation in non-
ablated and ablated tissue regions before and after electronic noise and motion correction
were compared.
Representative log10–scaled echo decorrelation, decibel–scaled integrated backscatter
(IBS), and corresponding triphenyl tetrazolium chloride (TTC) stained tissue histology im-
ages are shown in Figure 1.3. In general, good correspondence between echo decorrelation
maps and tissue histology (Figure 1.3 B and E) was seen in comparison to IBS maps (Figure
1.3 A and D).
Mean and standard error values of the log10-scaled mean echo decorrelation within ab-
lated tissue regions and non-ablated tissue regions for the 12 unfocused exposures, the 15
focused exposures, and the combined 27 exposures producing a thermal lesion are shown in
Figure 1.4 A–C. The log10–scaled mean echo decorrelation within ablated regions was signif-
icantly greater than in non–ablated regions for unfocused exposures (mean±standard error
−3.82±0.26 ablated; −4.15±0.26 non–ablated; t=1.70, p=5.83±10−2, N=12), for focused
exposures (−4.37±0.18 ablated; −4.63±0.13 non–ablated; t=2.45, p=2.58·10−2, N=15),
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Figure 1.3: Representative IBS (A and D), echo decorrelation (B and E), and segmented
triphenyl tetrazolium chloride (TTC) stained tissue histology (C and F) images for bulk
ultrasound (top row) and HIFU (bottom row) ablation. In the TTC–stained tissue sec-
tions, the outer blue boundary indicates the margin of incomplete ablation (TTC uptake in
blanched tissue regions) while the inner white boundary indicates the margin of completed
ablation (no TTC uptake).
and for all exposures combined (−4.13±0.16 ablated; −4.42±0.14 non–ablated; t=2.71,
p=5.92·10−3, N=27). The log10–scaled echo decorrelation within non–ablated regions was
significantly reduced by correction for noise and motion (t=−7.45, p=3.29·10−8, N=27).
Corresponding ROC curves for each group of experiments are shown in Figure 1.4 D–
F. Local ablation was predicted significantly better than chance by both echo decorrela-
tion and IBS for the 12 unfocused exposures (echo decorrelation AUC=0.58, p =3.12·10−4;
IBS AUC=0.60, p=1.11·10−5), for the 21 focused exposures (echo decorrelation AUC=0.69,
p=4.74·10−5; IBS AUC=0.64, p=3.10·10−3), and for the combination of all 33 exposures
(echo decorrelation AUC=0.69, p=1.00·10−12; IBS AUC=0.60, p=2.02·10−7). For the ROC
curves computed from all 33 trials, the AUC for echo decorrelation was significantly greater
for than for IBS (p=1.76·10−7).
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Figure 1.4: Mean and standard error of log10–scaled uncorrected and corrected echo decor-
relation in non–ablated and ablated regions for ex vivo bulk ultrasound (A), HIFU (B), and
combined bulk ultrasound and HIFU (C) ablations; ROC curves for bulk ultrasound (D),
HIFU (E), and combined bulk ultrasound and HIFU (F) ablations.
These preliminary in vitro results indicate that echo decorrelation imaging is a successful
predictor of local ablation. Consistent with previous studies, ablation prediction by echo
decorrelation was more successful than prediction by integrated backscatter (Mast et al.,
2008; Subramanian et al., 2014). Real–time monitoring by echo decorrelation imaging is
thus a promising approach for real time prediction of heat–induced cell death during clinical
thermal ablation treatments, including minimally invasive radiofrequency and HIFU abla-
tion. Optimization of imaging parameters, including decreasing the time between sonication
and imaging cycles and optimizing the pulse–echo image frame rate, and optimal threshold
design for treatment control may further improve tissue ablation prediction performance,
increasing the utility of echo decorrelation for treatment monitoring.
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1.2 Research hypotheses and specific aims
Our overall research objective is to provide clinicians with a real time, ultrasound–based
imaging approach to predict thermal–induced cell death during thermal ablation. The cen-
tral hypothesis of this study is that ultrasound echo decorrelation accurately predicts in
vivo ultrasound thermal ablation. To test this hypothesis the following specific aims were
completed:
1.2.1 Specific aim 1: Test ultrasound echo decorrelation’s cell–death prediction
performance
In vivo pulse–echo imaging of HIFU and bulk ultrasound thermal ablation were per-
formed on rabbit liver parenchyma and VX2 tumor. Ablation and imaging were performed
using the same image–ablate arrays, allowing precise comparison of image results and ablated
tissue histology. The prediction performance of echo decorrelation before and after motion
compensation was assessed by quantitatively comparing it with triphenyl tetrazolium chlo-
ride (TTC) stained gross histology and then computing its receiver operating characteristic
(ROC) curves. For comparison, the decibel–scaled integrated backscatter (IBS) and ROC
curves were also computed.
1.2.2 Specific aim 2: Establish design criteria for successful clinical translation
of cell–death prediction by echo decorrelation
To achieve real time thermal ablation guidance and monitoring, the effects of a realistic
clinical setting must be understood. Additionally, echo decorrelation thresholds which indi-
cate the desired clinical end effect must be established. In this study, optimal thresholds for
echo decorrelation monitoring and control of HIFU and bulk thermal ablation of normal liver
and VX2 tumor were determined. The effects of artifactual echo decorrelation due to in vivo
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tissue motion were also assessed by increasing the inter–frame time for echo decorrelation
computation. These parameters will aid system and ablation control algorithm design for
future clinical thermal ablation experiments.
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Chapter II
Motion–Corrected Echo Decorrelation Imaging of In
Vivo HIFU and Bulk Ultrasound Ablation in Rabbit
Liver and VX2 Tumor
2.1 Introduction
The ability of echo decorrelation imaging to accurately predict local heat–induced cell
death in rabbit liver and VX2 tumor tissue was tested using pulse–echo ultrasound data
recorded during in vivo high–intensity focused ultrasound (HIFU) and bulk ultrasound ther-
mal ablation experiments. The effect of tissue movement on echo decorrelation ablation
prediction was investigated and optimal thresholds for ablation prediction were determined.
Materials and methods used for the experiments, image formation, and data analysis are
described below. All animal experiments were performed according to protocols approved
by the University of Cincinnati Institutional Animal Care and Use Committee (IACUC).
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2.2 Materials and methods
2.2.1 VX2 tumor model
The VX2 tumor used for this study has been widely used for liver tumor therapy re-
search as it easily grows in rabbit liver and develops into discrete lesions (Wu et al., 2009).
Viable VX2 tumor fragments were implanted in each of the three main liver lobes of New
Zealand white rabbits and allowed to grow for two weeks (Figure 2.1). Thirty–eight tumors
successfully grew out of the 42 implanted tumor fragments. Gross tumor images within the
pulse–echo imaging plane were assessed. For the tissue sections facing one another, effective
tumor diameters [i.e., diameters of circles with area equal to measured tumor areas (Mast
et al., 2011)] were computed and the maximum of these two effective diameters was recorded.
Tumor diameters were 8.4 ± 3.3 mm for two weeks growth (N=23). Of these 23 tumors,
the 14 used for in vivo ablation trials described below measured 7.9 ± 3.5 mm in diameter
(Appendix Table 4.2).
2.2.2 Thermal ablation experiments
Ablation and imaging were performed using custom 64 element, 5×24 mm2 linear image–
ablate arrays with >40% pulse–echo fractional bandwidth for imaging and >40 W available
acoustic power for therapy, controlled by the Iris 2 ultrasound imaging and therapy system
[Ardent Sound Mesa, AZ, USA; Barthe et al. (2004)]. Pulse–echo imaging was performed
with a single transmit focal depth (3.5 cm, F–number=4).
The setup for these in vivo experiments is shown in Figure 2.1. In procedures performed
on 11 animals, the animal was anesthetized and its liver was exposed. The tumor was located
visually on the surface of the liver and indelible marks were made on the surface to guide
probe placement onto the tumor. Alignment with the tumor was verified by visualizing the
tumor in the B–mode (brightness mode) image. The array aperture was placed parallel
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Figure 2.1: Experimental setup for focused and unfocused ultrasound exposures of in vivo
rabbit liver. Image–ablate arrays (A) were held by a three–dimensional positioning arm (B).
The liver lobe (C) with implanted VX2 tumor (D) was placed on an acoustic gel coupling
pad (E) and/or acoustic absorber pad (F) before performing imaging and thermal ablation.
to the liver capsule surface at a distance of 23 mm using a water–filled standoff with an
acoustically transparent membrane window (Tegaderm, 3M, St Paul, MN, USA). Coupling of
the membrane to the tissue was achieved with an acoustic transmission gel (LithoClear, Next
Medical Products, Bellingham, WA, USA). To achieve accurate registration between tissue
histology and ultrasound images, the probe was fixed by a three–dimensional positioning arm
(Atlas Multifunctional Arm, Medical Intelligence, Schwabmu¨nchen, Germany) to minimally
compress the liver. A gel acoustic coupling pad (Aquaflex, Fairfield, NJ, USA) or rubber
acoustic absorber pad (Aptflex F28, Precision Acoustics Ltd., Dorchester, Dorset, UK) were
placed underneath the liver tissue to limit heating from reflections at the tissue–absorber
boundary and to constrain the liver lobe’s shape, allowing accurate registration of tissue
viability and parameter maps.
Thermal lesions were formed in VX2 tumor and liver regions using continuous–wave
sonications with center frequency fc = 5.00, 5.05, 5.20, or 5.40 MHz (Appendix Table 4.1).
For bulk ablation (N=10), a 64–element aperture fired pulses of 50–63 W/cm2 in situ spatial–
peak, temporal–peak intensity (Isptp) for 7–9 sonication pulses, totaling 76.5 s total ablation
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time (71% duty cycle). For HIFU ablation (N=13), a 64–element aperture electronically
focused at a single focal point 2 mm into the tissue fired 6–9 pulses with 911–1351 W/cm2
in situ Isptp (spatial–peak, temporal–peak intensity), resulting in 31.5 s total ablation time
(20% duty cycle). The in situ Isptp was computed from simulated acoustic fields of the
linear image–ablated array using methods described by Mast et al. (2007). Representative
simulations for focused and unfocused exposures are illustrated in Figure 2.2.
To assure that viability maps in the image–treat plane could be obtained for HIFU
ablation experiments, two thermal lesions used as registration marks were formed by fir-
ing unfocused sub–apertures comprising elements, 1–10, and then elements 55–64. Each
sub–aperture fired pulses of 59 W/cm2 until a visible lesion was seen on the liver surface.
Registration mark formation was confirmed by simulation (Mast et al., 2005) not to elevate
temperature at the focus position above 2 ◦C.
After each sonication pulse, 114 frames of beamformed, radiofrequency echo signals were
captured at a rate of 118 frames per second, beginning <10 ms or <1.1 s after each sonication
pulse, using a PC–based data acquisition system with a 33 MHz sampling rate (CompuScope
CS 14200, Gage Applied Technologies, Montreal, QC, Canada).
2.2.3 Image processing
Before further processing, echo signals were demodulated with a 5.0 MHz center frequency
and decimated to in–phase and quadrature (IQ) components with a sampling rate of 5.56
MHz. This data acquisition was performed both for ablation trials and for matching sham
trials, used for estimation and correction of decorrelation artifacts.
The IQ echo signals were processed to construct integrated backscatter (IBS) and decorre-
lation per millisecond (referred to as echo decorrelation in this thesis) images using Equations
1.2–1.8 found in Chapter 1. Tissue boundaries were manually segmented in the ultrasound
images to eliminate echoes from outside the liver lobe. Echo decorrelation and IBS were
34
Azimuthal (mm)
R
an
ge
 (m
m)
 
 
−10 −5 0 5 10
0
5
10
15
20 0
10
20
30
40
50
(a)
Elevation (mm)
R
an
ge
 (m
m)
 
 
−10 −5 0 5 10
0
5
10
15
20
10
20
30
40
50
(b)
Azimuthal (mm)
R
an
ge
 (m
m)
 
 
−10 −5 0 5 10
0
5
10
15
20 0
0.5
1
1.5
2
(c)
Elevation (mm)
R
an
ge
 (m
m)
 
 
−10 −5 0 5 10
0
5
10
15
20 0
0.5
1
1.5
2
(d)
Figure 2.2: Simulated intensity beams for the focused (2.2a and 2.2b; electronically focused
to 25 mm) and unfocused (2.2c and 2.2d; electronically focused to∞) linear–array apertures
deployed for these in vivo experiments. The beams were simulated for the field just beyond
the 22 mm standoff.
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calculated within the segmented tissue boundaries as seen in the ultrasound images. The
Gaussian window function (Equation 1.3) width parameter (σ) for decorrelation and IBS
calculation was 1.0 mm.
The local instantaneous decorrelation was averaged over each frame group (i.e., ensem-
ble averaged) containing 112 frames taken after each sonication cycle (Figure 2.3). The
cumulative decorrelation was defined as the temporal maximum of the ensemble–averaged
∆local.
Estimates of artifactual cumulative decorrelation obtained from corresponding sham tri-
als, denoted ∆sham, were used to construct corrected cumulative decorrelation, denoted
∆corrected(y, z, t), from uncorrected cumulative decorrelation, denoted ∆uncorrected, using Equa-
tion 1.7. This correction was only applied at locations where ∆uncorrected exceeded a dynami-
cally set threshold defined as 10 times the minimum of the corresponding ∆sham. At locations
where Equation 1.7 would result in corrected values less than zero, ∆corrected was set equal
to the minimum value of ∆sham.
B–mode images were constructed from the log10–scaled envelopes (|p(y, z, t)|) of the IQ
data and displayed on a 60 dB dynamic range. Hybrid B–mode/decorrelation and B–
mode/IBS images were constructed by overlaying the B–mode and log10–scale decorrela-
tion images and decibel–scaled IBS images (Mast et al., 2008). All image processing was
performed in MATLAB (The MathWorks, Natick, MA, USA).
2.2.4 Analysis of imaging delay effects
Post sonication temperature decay effects on echo decorrelation measurements were in-
vestigated because relatively high local echo decorrelation decay rates were observed after
focused sonication (Figure 2.3a). An analytic solution to the homogeneous bio–heat transfer
equation without perfusion was used to estimate these temperature decay effects. Green’s
functions were used to solve the bio–heat transfer equation without perfusion analytically
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(a)
(b)
Figure 2.3: Representative echo decorrelation time history at a local echo decorrelation
maximum: cumulative sham (∆sham) and instantaneous (∆local), ensemble-averaged (∆EA),
uncorrected cumulative (∆uncorrected), and corrected cumulative (∆corrected) echo decorrelation
values for in vivo HIFU (2.3a) and bulk (2.3b) ultrasound thermal ablation. Tissue was
sonicated (ON) 0.7 s for HIFU and 6–7.5 s for bulk thermal ablation. Echo decorrelation
was calculated from ultrasound pulse–echo images acquired during 2.8–3.3 s rest periods
(OFF) for HIFU and 2.5–5 s for bulk thermal ablation.
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(Ozisik et al., 1993):
∂T (~r, t)
∂t
= K∇2T (~r, t), (2.1)
where T (~r, t) is the spatio–temporal temperature elevation profile, r is the magnitude of the
position vector ~r, and K is the thermal diffusivity of liver tissue. Assuming radial symmetry,
the Green’s function for this system in spherical coordinates is (Ozisik et al., 1993)
G(~r) =
e−r
2/(4Kt)
8pi3/2(Kt)3/2
. (2.2)
The initial temperature condition was proportional to the intensity beam of the acoustic
source. An approximate representation of this heating pattern was assumed sufficient for an
order–of–magnitude estimate of the imaging delay effects. To this end, a Gaussian distribu-
tion was used for the initial condition:
Ti(~r) = T0e
− r2
2σ2 , (2.3)
where the Gaussian width parameter σ was set equal to 10 mm for unfocused ablation and
0.1 mm for focused ablation. These widths were estimated by minimizing the mean–squared
error between a Gaussian and simulated transverse beam profiles containing the spatial
peak–temporal peak intensity (Figures 2.4a and 2.4c). The beam profiles were obtained
from simulated acoustic fields of the unfocused (focal depth = ∞) and focused (focal depth
= 25 mm) linear image–ablate array (Mast et al., 2007). The analytic solution for the
temperature profile post sonication follows as
T (~r, t) =
∫
V0
G(~r − ~r0, t)Ti(~r0)dV0 = T0 σ
3e
− r2
4Kt+2σ2
(2Kt+ σ2)3/2
, (2.4)
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where the thermal diffusivity of liver tissue was K = 0.137 (mm2/s) (Mast et al., 2005). The
estimated maximum temperature decrease during the <10 ms delay was 20% and < 0.1%
for the focused and unfocused trials. The estimated maximum temperature decrease during
the 1.1 s delay was > 90% and 0.5% for the focused and unfocused trials. For these reasons,
the focused trials with a 1.1 s delay were removed from this study.
2.2.5 Tissue processing
After ablation, the animal was euthanized. The liver lobes were removed and sectioned
parallel to the image–ablate plane with a scalpel. Sectioning was performed within 2 hours
post–ablation. The surface closest to the image–ablate plane was stained with a 2% (w/v)
solution of triphenyl tetrazolium chloride (TTC; Sigma–Aldrich, St. Louis, MO, USA) in 0.1
M phosphate–buffered saline (Sigma–Aldrich, St. Louis, MO, USA) for 20 minutes with the
image–ablate plane face down in the TTC well. TTC uptake indicates metabolically active
tissue, while no TTC uptake indicates inactive tissue (Scheffer et al., 2014).
Tissue images were manually segmented to delineate boundaries of the liver lobes, VX2
tumors, regions of reduced TTC stain uptake, and regions of no TTC uptake. Binary masks
were then created to distinguish ablated tissue (defined as no TTC uptake) from non–ablated
tissue (reduced or full TTC uptake) and to distinguish treated tissue (reduced or no TTC
uptake) from untreated tissue (full TTC uptake). Separate masks were created for liver and
tumor regions for direct comparison to echo decorrelation and IBS images.
2.2.6 Statistical analysis
Separate statistical analyses were performed for focused exposures in liver and VX2
tumor, unfocused exposures in liver and VX2 tumor, and the combination of all exposures
in liver and VX2 tumor.
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Figure 2.4: Gaussian fits for the simulated focused (Figure 2.4a) and unfocused (Figure 2.4c)
intensity beam shapes used to approximate σ in Equation 2.3. The T/T0 decay for HIFU
(Figure 2.4b) and bulk (Figure 2.4d) ablation illustrates that effects of the delay times were
not negligible for the HIFU ablations imaged 1.1 s after the end of sonication, but that these
effects were negligible for unfocused ablations imaged 1.1 s after sonication.
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Focused exposure trials were excluded from the final analysis if the post–focal lesion
extended beyond a depth 2 mm from the dorsal side of the liver lobe. Additionally, focused
exposures imaged > 1 s after sonication were excluded. Focused and unfocused trials were
also excluded if the corresponding TTC–stained gross histology was inconclusive. Twenty–
six trials were excluded, leaving 23 for further analysis.
Significant reduction of noise decorrelation by correction was tested by comparing log10–
scaled mean echo decorrelation in non–ablated regions before and after correction using a
paired one–tailed t test with significance criterion p < 0.05.
Significant increase of log10–scaled mean echo decorrelation within ablated regions was
tested by comparing log10–scaled mean echo decorrelation in the ablated regions and non–
ablated regions using unpaired and paired one–tailed t tests with the significance criterion
p < 0.05. Significant differences between log10–scaled mean echo decorrelation in non–
ablated liver and non–ablated VX2 tumor were tested using unpaired and paired two–tailed
t tests with the significance criterion p < 0.05. Significant differences between log10–scaled
mean echo decorrelation in ablated liver and ablated VX2 tumor were tested using unpaired
and paired two–tailed t tests with the significance criterion p < 0.05. The unpaired t test
was used to detect differences in the collective average log10–scaled mean echo decorrelation.
The paired t test was used to detect differences between paired (i.e., non-ablated and ablated
regions in each tissue section) log10–scaled mean echo decorrelation. The same analysis
described above was also performed for decibel–scaled mean IBS.
Receiver operating characteristic (ROC) curves were constructed by comparing thresh-
olded corrected echo decorrelation and IBS images to tissue ablation maps. The ROC curve
is the false–positive rate (1−specificity) versus the true–positive rate (sensitivity) for each
threshold value (Hanley et al., 1982). The 1−specificity and the sensitivity are defined as
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Sensitivity =
TP
TP + FN
(2.5)
1− specificity = FP
FP + TN
, (2.6)
where TP is the number of correct positive classifications, TN is the number of correct
negative classifications, FP is the number of incorrect positive classifications, and FN is the
number of incorrect negative classifications.
The area under the curve (AUC) was used to determine the predictive success of param-
eter images. An AUC of 1 indicates that the parameter image predicted the tissue ablation
perfectly, whereas an AUC of 0.5 means that the prediction was no better than chance
(Hanley et al., 1982).
Thresholds for optimal prediction of tissue ablation for echo decorrelation and IBS were
determined by selecting the threshold corresponding to the point nearest to the top left–hand
corner of the ROC plot (Krzanowski et al., 2009). This approaches weights the importance
of specificity and sensitivity for ablation prediction equally.
For assessment of statistical significance, effective sample sizes (Neff) were determined by
estimating the number of independent ablation predictions from the total number of samples
(Ntotal):
Neff
Ntotal
=
∆z∆yγ
d2
, (2.7)
where γ = pi/
√
12 is the number of unit–diameter circles per unit–area rectangle for the
maximum hexagonal packing density (Subramanian et al., 2014). The range and azimuthal
echo decorrelation map pixel dimensions are ∆z and ∆y. In Equation 2.7, d is the Gaussian
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full width at half maximum:
d = 2
√
2 ln(2)σ, (2.8)
where σ=1.0 mm is the Gaussian width parameter (Subramanian et al., 2014). The sta-
tistical significance of measured AUC values vs. the null hypothesis (AUC=0.5) was then
calculated in MATLAB using a general model for the AUC standard error (Hanley et al.,
1982) (significance criterion p <0.05, one–tailed). Statistical significance of differences be-
tween AUC values for corrected echo decorrelation and IBS was calculated in R (pROC
package; R Foundation for statistical Computing, Vienna, Austria) by calculating the Z–
statistic (Ztotal) for Ntotal using the method of DeLong et al. (1988) (significance criterion
p <0.05, two–tailed). The effective p–value was determined by correcting Ztotal using the
equation:
Zeff =
Ztotal√
Ntotal
Neff
, (2.9)
where Zeff is the effective Z–statistic. The effective significance peffective (significance crite-
rion p <0.05, two–tailed) was then determined from Zeff using the cumulative distribution
function (cdf) and the equation
peffective = 2(1− cdf(Zeff)). (2.10)
2.2.7 Analysis of inter–frame time effects
To determine the effect of imaging inter–frame time in echo decorrelation and IBS abla-
tion prediction performance, uncorrected and corrected echo decorrelation and IBS images
were constructed for τ (inter–frame time) = 8.5, 42.4, 84.7, 127.1, 169.5, 211.9, 254.2, 508.5,
and 847.5 ms for focused and unfocused exposures in liver and VX2 tumor. Echo decorre-
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lation and IBS images were registered and quantitatively compared with the corresponding
histology and the ROC curves and AUCs were computed as described in the previous section.
2.3 Results
Sham cumulative decorrelation (I), tissue histology (II), cumulative decorrelation (III),
and integrated backscatter (IBS) (IV) images for all of the 23 trials are shown in Figure
2.5 A–W. In the echo decorrelation and IBS images, the threshold for optimal prediction of
ablation (log10–scaled echo decorrelation per millisecond: −3.1; IBS: 3.86 dB) is indicated by
the yellow line. The white line indicates the tissue boundaries as seen in the B–mode images.
In the TTC–stained tissue sections, the red, blue, green, and black lines indicate tissue,
treated, ablated, and tumor regions. For focused exposures, Figures 2.5 A–M, generally
better correspondence with histology was seen for corrected echo decorrelation than for IBS.
For unfocused exposures, Figures 2.5 N–W, comparable correspondence between IBS (IV),
corrected echo decorrelation (III), and histology (II) was seen.
Elevated echo decorrelation within non–ablated liver regions due to noise and motion was
significantly reduced using Equation 1.7 for the focused exposures, unfocused exposures, and
all exposures combined (Table 2.1). Decorrelation was significantly reduced in non–ablated
tumor regions for focused exposures and all exposures combined; however, there was not a
significant reduction for the unfocused exposures. Reduction of decorrelation within ablated
tissue and tumor regions was marginally significant for focused exposures and unfocused
exposures and significant for the all exposures combined.
The mean and standard error values of the log10–scaled mean corrected echo decorrelation
per millisecond and the decibel–scaled mean IBS within non–ablated and ablated regions for
unfocused exposures in liver (N=10) and tumor (N=8), focused exposures in liver (N=13)
and tumor (N=6) and the combined exposures in liver (N=23) and tumor (N=14) are
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Figure 2.5: From left to right are the log10-scaled sham cumulative echo decorrelation (I),
corresponding segmented triphenyl terazolium chloride (TTC) stained image–ablated plane
histology (II), log10-scaled cumulative corrected echo decorrelation (III), and decibel–scaled
cumulative integrated backscatter (IBS) (IV) for HIFU ablation (sub–figures A–M) and bulk
ablation (sub–figures N–W). The white line indicates tissue boundaries as seen in the B–
mode images. In the echo decorrelation and IBS images, the threshold for optimal prediction
of ablation (log10–scaled echo decorrelation per millisecond: -3.1; IBS: 3.86 dB) is indicated
by the yellow–dotted line. In the TTC–stained tissue sections, the red, blue, green, and
black boundaries indicate the tissue, treated, ablated, and tumor regions.
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Figure 2.5 continued.
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Figure 2.5 continued.
Exposure Liver VX2 tumor
HIFU −6.03 (2.97·10−5) −2.73 (0.02)
Bulk −2.78 (0.01) −1.07 (0.20)
All exposures combined −5.67 (6.35·10−6) −2.40 (0.02)
Table 2.1: The t–statistic and p–value for comparisons between log10–scaled mean echo
decorrelation in non–ablated liver and VX2 tumor regions before and after correction.
Exposure Liver VX2 tumor
HIFU −2.07 (0.04) −2.35 (0.05)
Bulk −1.92 (0.04) −2.20 (0.03)
All Exposures Combined −2.71 (7.46·10−3) −2.33 (0.02)
Table 2.2: The t–statistic and p–value for comparisons between log10–scaled mean echo
decorrelation in ablated liver and VX2 tumor regions before and after correction.
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illustrated in Figures 2.13, 2.14, and 2.15 and tabulated in Table 2.3.
For unpaired comparisons, the log10–scaled mean corrected echo decorrelation within
ablated liver regions was significantly greater than in non–ablated regions for focused expo-
sures, unfocused exposures, and all exposures combined (Tables 2.4). In VX2 tumor, the
log10–scaled mean corrected echo decorrelation within ablated regions was marginally greater
than in non–ablated regions for focused exposures, unfocused exposures, and all exposures
combined. Differences in the log10–scaled mean corrected echo decorrelation within non—
ablated liver and tumor were significant for focused exposures, not significant for unfocused
exposures and marginally significant for all exposures combined. The log10–scaled mean
corrected echo decorrelation within ablated liver and tumor were not significantly different.
For unpaired comparisons, the decibel–scaled mean IBS within ablated liver regions was
significantly greater than in non–ablated regions for focused exposures and all exposures
combined and not significant greater for unfocused exposures (Table 2.6). In VX2 tumor, the
decibel–scaled mean IBS within ablated regions was marginally greater than in non–ablated
regions for focused exposures, unfocused exposures, and all exposures combined. Differences
in the decibel–scaled mean IBS within non–ablated liver and tumor were significant for
focused exposures but not significant for unfocused exposures and all exposures combined.
The decibel–scaled mean IBS within ablated liver and tumor were not significantly different.
Liver VX2 tumor
Exposure Non–ablated Ablated Non–ablated Ablated
HIFU −3.88 (0.14) −3.04 (0.30) −3.06 (0.23) −2.89 (0.40)
Bulk −3.05 (0.30) −2.32 (0.23) −2.57 (0.70) −2.47 (0.31)
All exposures combined −3.54 (0.17) −2.64 (0.20) −2.90 (0.26) −2.61 (0.24)
Table 2.3: Mean and standard error of log10–scaled mean echo decorrelation per millisecond
in non–ablated and ablated regions.
The results for paired comparisons are tabulated in Tables 2.7 and 2.8. In liver, the log10–
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Figure 2.13: Mean and standard error of corrected log10–scaled echo decorrelation per mil-
lisecond (Figure 2.13a) and decibel–scaled IBS (Figure 2.13b) in non–ablated and ablated
regions for focused exposures in liver and VX2 tumor. The single, double, and triple asterisks
correspond to p ≤ 0.05, p ≤ 10−2, and p ≤ 10−3.
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Figure 2.14: Mean and standard error of corrected log10–scaled echo decorrelation per mil-
lisecond (Figure 2.14a) and decibel–scaled IBS (Figure 2.14b) in non–ablated and ablated
regions for unfocused exposures in liver and VX2 tumor. The single, double, and triple
asterisks correspond to p ≤ 0.05, p ≤ 10−2, and p ≤ 10−3.
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Figure 2.15: Mean and standard error of corrected log10–scaled echo decorrelation per mil-
lisecond (Figure 2.15a) and decibel–scaled IBS (Figure 2.15b) in non–ablated and ablated
regions for the group of all exposures in liver and VX2 tumor. The single, double, and triple
asterisks correspond to p ≤ 0.05, p ≤ 10−2, and p ≤ 10−3.
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Non–ablated vs. ablated Liver vs. VX2 tumor
Exposure Liver VX2 tumor Non–ablated Ablated
HIFU 2.89 (4.71 · 10−3) 0.40 (0.35) 3.25 (4.73 · 10−3) 0.29 (0.78)
Bulk 1.98 (0.03) 0.15 (0.44) 0.74 (0.47) −0.41 (0.69)
All exposures combined 3.50 (6.02 · 10−4) 0.80 (0.22) 2.07 (0.05) 0.09 (0.93)
Table 2.4: The unpaired t–statistic and p–value for comparisons between log10–scaled mean
echo decorrelation in ablated and non–ablated liver and VX2 tumor regions.
Liver VX2 tumor
Exposure Non–ablated Ablated Non–ablated Ablated
HIFU 1.78 (0.47) 9.56 (2.86) 7.43 (2.98) 8.46 (3.74)
Bulk 7.44 (1.78) 10.14 (1.75) 6.49 (3.37) 7.36 (1.90)
All exposures combined 4.10 (0.97) 9.89 (1.55) 7.12 (2.16) 7.73 (1.68)
Table 2.5: Mean and standard error of decibel–scaled mean integrated backscatter in non–
ablated and ablated regions.
Non–ablated vs. ablated Liver vs. VX2 tumor
Exposure Liver VX2 tumor Non–ablated Ablated
HIFU 3.40 (1.50 · 10−3) 0.22 (0.42) 2.72 (0.01) −0.23 (0.82)
Bulk 1.08 (0.15) 0.24 (0.41) −0.26 (0.80) −1.07 (0.30)
All exposures combined 3.28 (1.10 · 10−3) 0.23 (0.41) 1.48 (0.15) −0.92 (0.37)
Table 2.6: The unpaired t–statistic and p–value for comparisons between decibel–scaled
mean integrated backscatter in ablated and non–ablated liver and VX2 tumor.
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scaled mean corrected echo decorrelation within ablated regions was significantly greater than
in non–ablated regions for focused exposures, unfocused exposures and all exposures com-
bined. In VX2 tumor, the log10–scaled mean corrected echo decorrelation within ablated
regions was marginally greater than in non–ablated regions for focused exposures and un-
focused exposures and marginally significant for all exposures combined. Differences in the
log10–scaled mean corrected echo decorrelation within non—ablated liver and tumor were
significant for focused exposures and not significant for unfocused exposures and for all ex-
posures combined. The log10–scaled mean corrected echo decorrelation within ablated liver
and tumor were not significantly different.
In liver, the decibel–scaled mean IBS within ablated regions were significantly greater
than in non–ablated regions for focused exposures and all exposures combined and marginally
greater for unfocused exposures (Table 2.8). In VX2 tumor, the decibel–scaled mean IBS
within ablated regions was not significantly greater than in non–ablated regions for focused
exposures and unfocused exposures and was significantly greater for all exposures combined.
Differences in the decibel–scaled mean IBS within non—ablated liver and tumor were not
significant for focused exposures and unfocused exposures but were marginally significant
for all exposures combined. The decibel–scaled mean IBS within ablated liver and tumor
were not significantly different.
Non-ablated vs. ablated Liver vs. VX2 tumor
Exposure Liver VX2 Tumor Non-ablated Ablated
HIFU 4.42 (1.54 · 10−3) 1.44 (0.12) 2.91 (0.03) NA
Bulk 2.23 (0.03) 1.69 (0.12) −0.59 (0.62) −0.91(0.39)
All exposures combined 4.07 (4.49 · 10−4) 2.18 (0.04) 1.48 (0.18) −0.54 (0.60)
Table 2.7: The paired t test t–statistic and p–value for comparisons between log10–scaled
mean echo decorrelation in ablated and non–ablated liver and VX2 tumor regions.
Corresponding ROC curves for each group of exposures are shown in Figures 2.16, 2.17,
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Non-ablated vs. ablated Liver vs. VX2 tumor
Exposure Liver VX2 Tumor Non-ablated Ablated
HIFU 3.46 (5.27 · 10−3) 1.29 (0.14) 2.31 (0.07) NA
Bulk 1.31 (0.11) 2.01 (0.09) 3.60 (0.07) −1.25 (0.25)
All exposures combined 3.20 (2.78 · 10−3) 2.22 (0.03) 2.36 (0.05) −1.26 (0.24)
Table 2.8: The paired t–statistic and p–value for comparisons between decibel–scaled mean
integrated backscatter in ablated and non–ablated liver and VX2 tumor.
and 2.18. The summary statistics for the ROC curve comparisons are tabulated in Tables
2.9– 2.13. Treated and ablated regions in liver were predicted significantly better than chance
(AUC=0.5) by corrected echo decorrelation and IBS for focused exposures, unfocused expo-
sures and all exposures combined (Tables 2.9 and 2.10). Treated and ablated regions in VX2
tumor were predicted significantly better than chance by corrected echo decorrelation for un-
focused exposures and all exposures combined (Table 2.11). Treated and ablated regions in
VX2 tumor were not predicted significantly better than chance by corrected echo decorrela-
tion for focused exposures. Treated regions in VX2 tumor were predicted significantly better
than chance by IBS for focused exposures, unfocused exposures and all exposures combined
(Table 2.12). IBS only predicted ablated VX2 tumor significantly better than chance for all
exposures combined.
Liver
Exposure Treated Ablated
HIFU 8.22 (< 1.00 · 10−12) 6.74 (< 1.00 · 10−12)
Bulk 2.95 (1.60 · 10−3) 3.30 (5.00 · 10−3)
All exposures combined 24.17 (< 1.00 · 10−12) 20.97 (< 1.00 · 10−12)
Table 2.9: The z–statistic and p–value for comparisons between AUC=0.5 and echo decor-
relation ablation prediction of treated and ablated liver regions.
Table 2.13 summarizes the comparisons between echo decorrelation and IBS ablation
prediction performance. In liver, corrected echo decorrelation predicted significantly better
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Liver
Exposure Treated Ablated
HIFU 3.80 (7.16 · 10−5) 3.01 (1.30 · 10−4)
Bulk 3.11 (9.00 · 10−4) 4.36 (1.00 · 10−12)
All exposures combined 17.35 (< 1.00 · 10−12) 15.83 (< 1.00 · 10−12)
Table 2.10: The z–statistic and p–value for comparisons between AUC=0.5 and IBS ablation
prediction of treated and ablated liver regions.
VX2 tumor
Exposure Treated Ablated
HIFU 1.44 (0.08) 1.31 (0.09)
Bulk 1.77 (0.04) 1.80 (0.04)
All exposures combined 3.54 (2.00 · 10−4) 3.80 (1.00 · 10−4)
Table 2.11: The z–statistic and p–value for comparisons between AUC=0.5 and echo decor-
relation ablation prediction of treated and ablated VX2 tumor regions.
VX2 tumor
Exposure Treated Ablated
HIFU 1.73 (0.04) 1.19 (0.12)
Bulk 1.72 (0.04) 0.33 (0.37)
All exposures combined 3.36 (4.00 · 10−4) 2.33 (0.01)
Table 2.12: The z–statistic and p–value for comparisons between AUC=0.5 and IBS ablation
prediction of treated and ablated VX2 regions.
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Figure 2.16: ROC curves illustrating prediction performance for tissue ablation (no TTC
uptake) (Figure 2.16a) and tissue treatment (reduced or no TTC uptake) (Figure 2.16b) by
corrected echo decorrelation (dotted lines) and IBS (dash–dotted lines) for focused exposures
in liver (red lines) and VX2 tumor (black lines).
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Figure 2.17: ROC curves illustrating prediction performance for tissue ablation (no TTC
uptake) (Figure 2.17a) and tissue treatment (reduced or no TTC uptake) (Figure 2.17b)
by corrected echo decorrelation (dotted lines) and IBS (dash–dotted lines) for unfocused
exposures in liver (red lines) and VX2 tumor (black lines).
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Figure 2.18: ROC curves illustrating prediction performance for tissue ablation (no TTC
uptake) (Figure 2.18a) and tissue treatment (reduced or no TTC uptake) (Figure 2.18b) by
corrected echo decorrelation (dotted lines) and IBS (dash–dotted lines) for both exposures
in liver (red lines) and VX2 tumor (black lines).
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than IBS for focused exposures and for the combined group. For unfocused exposures, IBS
predicted ablated regions significantly better than echo decorrelation for ablated regions. In
VX2 tumor, there were no significant differences between echo decorrelation and IBS.
Liver VX2 tumor
Exposure Treated Ablated Treated Ablated
HIFU 2.83 (0.002) 2.51 (0.01) −0.24 (0.41) 0.11 (0.46)
Bulk −0.60 (0.27) −1.81 (0.04) 0.01 (0.50) 0.84 (0.20)
All exposures combined 6.07 (1·10−5) 4.96 (1·10−5) 0.18 (0.43) 1.29 (0.10)
Table 2.13: The z–statistic and p–value for comparisons between AUCs for echo decorrelation
and IBS ablation prediction of regions of treated and ablated regions in and VX2 tumor.
The optimal thresholds and corresponding sensitivities and specificities for echo decor-
relation and IBS are outlined in Table 2.14. At the optimal threshold for prediction of
ablated regions, corrected echo decorrelation’s sensitivity (TPR) was better than its speci-
ficity (1−FPR) for unfocused exposures and focused exposures. For all exposures combined,
echo decorrelation’s sensitivity was better than its specificity for ablation prediction in VX2
tumor; however, the opposite was observed for ablation prediction in liver. Figure 2.19
illustrates sensitivity and specificity trade offs observed for all exposures combined for log10–
scaled echo decorrelation thresholds −12 to −1. For higher thresholds, the specificity is
enhanced at the cost of increasingly lower sensitivity. For low thresholds, the sensitivity is
enhanced at the cost of increasingly lower specificity.
Figures 2.20a and 2.20b illustrate prediction performance, as measured by the AUC, of
echo decorrelation and IBS computed for inter–frame times 8.5, 42.4, 84.7, 127.1, 169.5, 211.9,
254.2, 508.5, and 847.5 ms. Greater AUCs for corrected echo decorrelation in comparison to
uncorrected demonstrate performance enhancement by noise correction. An overall decrease
in uncorrected and corrected AUC was observed for larger inter–frame times; however, the
decrease was less for corrected echo decorrelation. In contrast, IBS AUC was unchanged for
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HIFU Ablation Ablated Normal tissue Ablated VX2 tumor
Decorrelation optimal threshold −3.70 −3.20
Sensitivity (TPR) 0.88 0.77
Specificity (1−FPR) 0.81 0.62
IBS optimal threshold 1.82 2.12
Sensitivity (TPR) 0.70 0.75
Specificity (1−FPR) 0.88 0.59
Bulk Ablation
Decorrelation optimal threshold −3.10 −3.20
Sensitivity (TPR) 0.70 0.75
Specificity (1−FPR) 0.57 0.60
IBS optimal threshold 3.86 2.98
Sensitivity (TPR) 0.61 0.68
Specificity (1−FPR) 0.69 0.45
All Exposures Combined
Decorrelation optimal threshold −3.40 −3.20
Sensitivity (TPR) 0.76 0.76
Specificity (1−FPR) 0.84 0.62
IBS optimal threshold 1.48 2.53
Sensitivity (TPR) 0.74 0.73
Specificity (1−FPR) 0.80 0.58
Table 2.14: Optimal thresholds and the corresponding sensitivity and specificity for corrected
echo decorrelation and IBS ablation prediction in liver and VX2 tumor.
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Figure 2.19: log10–scaled echo decorrelation ablation prediction sensitivities (dashed line)
and specificities (dotted line) observed for the group of all exposures in liver (red) and VX2
tumor (black).
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larger inter–frame times.
2.4 Discussion
Previous echo decorrelation imaging studies have shown promising results for radiofre-
quency and ultrasound ablation prediction (Mast et al., 2008; Subramanian et al., 2014; Fos-
night et al., 2014). The utility and possible limitations of echo decorrelation tumor ablation
monitoring in a living subject, where motion could limit echo decorrelation’s performance,
are discussed below.
Artifactual decorrelation due to tissue displacement and strain/compression caused by
respiration, in the context of thermal ablation of liver cancer, and electronic noise can limit
ultrasound–based ablation monitoring (Hooi et al., 2015). Table 2.1 illustrates a significant
reduction of artifactual echo decorrelation in the non–ablated regions for focused exposures,
unfocused exposures, and all exposures combined in liver. Figures 2.20a and 2.20b illustrate
that the prediction performance decrease was marginally significant for both focused and
unfocused exposures as the inter–frame time increased, possibly indicating an increase of
motion–induced decorrelation as previously seen by Subramanian et al. (2014) and Hooi et al.
(2015). In contrast, IBS ablation prediction performance decrease for large inter–frame times
was insignificant. As IBS is a measure of backscatter energy, as defined in Equation 1.8, the
unchanged IBS AUCs seen in Figures 2.20a and 2.20b for greater inter–frame times suggests
that the backscatter energy was constant in comparison to echo decorrelation. These results
indicate that echo decorrelation and IBS were relatively unaffected by inter–frame times as
large as 847.5 ms for this in vivo model.
The ROC results illustrated in Figures 2.16, 2.17, and 2.18 indicate that echo decorre-
lation imaging is a successful predictor of local ablation. In liver, echo decorrelation and
integrated backscatter (IBS) prediction performance was significantly better than chance
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Figure 2.20: AUCs for uncorrected (red–dash line) and corrected (red–dotted line) echo
decorrelation and IBS (black–solid line) computed for τ (inter–frame time) = 8.5, 42.4, 84.7,
127.1, 169.5, 211.9, 254.2, 508.5, and 847.5 ms. Ablation prediction performance was tested
for focused (a) and unfocused (b) exposures in liver.
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(AUC=0.5) (Tables 2.9 and 2.10). In tumor, echo decorrelation and IBS predicted tumor
ablation significantly better than chance for all exposures combined (Tables 2.11 and 2.12).
For the unfocused exposures and focused exposures, AUC values for tumor were insignificant
or marginally significant, consistent with marginal differences between echo decorrelation in
ablated and non–ablated tumor (Figures 2.13, 2.14a, and 2.15a). The lower statistical sig-
nificance is in part due to the smaller number of predictions in tumor in comparison to the
number of predictions in liver.
Ablation prediction in liver by echo decorrelation was significantly more successful than
prediction by IBS for the focused exposures and for all exposures combined, consistent with
previous observations (Mast et al., 2008; Subramanian et al., 2014; Fosnight et al., 2014).
This result implies echo decorrelation imaging can predict ablation better than conventional
B–mode (brightness–mode) ultrasound imaging, as image brightness is proportional to the
echo amplitude (Szabo et al., 2004). However, for the unfocused exposure group, IBS pre-
dicted ablated liver significantly better than echo decorrelation. Echo decorrelation did not
predict ablated VX2 tumor significantly better than IBS for the focused exposures, unfocused
exposures, or for all exposures combined.
Differences in echo decorrelation in liver and tumor were seen for the unfocused group.
There was a trend of lower decorrelation in ablated tumor than in ablated liver (Figure 2.14);
however, these differences were not significant (Table 2.4 and 2.7). This result is addition-
ally highlighted by sub–figures 2.5 Q, R and T, where the log–scaled echo decorrelation is
generally lower in ablated tumor regions in comparison to ablated liver. This trend may be
due to the content and/or structure of the tumor tissue as a result of tumor size. For a VX2
rabbit liver cancer model, Wu et al. (2009) observed necrosis development in the tumor cen-
ter, thickening of the tumor border, and a increased blood stasis in the tumor rim as tumor
size increased. These changes may lead to varying micro–structural changes during thermal
ablation. This implies that tumor heating and/or echo decorrelation’s ablation prediction
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performance may depend on the size of the VX2 tumor.
Echo decorrelation’s 2.35 mm spatial resolution for a window size of 1 mm, determined
using Equation (2.8), might explain the insignificant differences between decorrelation in
non–ablated vs. ablated regions observed for focused exposures, unfocused exposures, and
all exposures combined in VX2 tumor. Hooi et al. (2015), using simulated echo decorrelation
images, showed that a correlation window size approximately 1/6 the expected lesion size
was most appropriate. For these experiments, the 1.00 mm window size was thus appropriate
for unfocused ablation (the approximate optimal window size, estimated from the Gaussian
beam models of Section 2.2.4, is 1.67 mm) but suboptimal for focused ablation (approximate
optimal window size 0.02 mm). For accurate imaging of focused ablation, improved echo
decorrelation performance could be achieved using a smaller correlation window size. To this
end, the pulse–echo image resolution must also be improved. Improved pulse–echo imaging is
achieved by utilizing more transmit imaging foci or increasing the imaging center frequency,
the transducer bandwidth, and/or the active aperture size (Szabo et al., 2004); however,
improved resolution will increase motion–induced decorrelation.
Another cause of poor prediction is lesion motion during treatment. Lesion movement
might lead to high false positive rates (i.e., low ablation contrast). The ablation prediction
performance for focused exposures would be more affected in comparison to the unfocused
exposures due to the larger ablated region.
These results indicate echo decorrelation imaging is a successful predictor of local abla-
tion, with potential for real–time ultrasound system implementation and successful clinical
translation. For most cases, echo decorrelation predicted ablated liver better than IBS and
predicted ablated VX2 tumor marginally better than IBS. Tissue motion effects were shown
to have little effect on echo decorrelation’s ablation prediction performance; however, focused
ablation prediction performance could potentially be enhanced by improving pulse–echo im-
age resolution. Additionally, enhancement of prediction performance could be achieved by
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leveraging three–dimensional volume ultrasound imaging systems, which inherently have
slower frame rates, as echo decorrelation’s performance was marginally affected by tissue
motion. These results suggest that echo decorrelation imaging merits further investigation
and has potential to improve real–time monitoring during HIFU thermal ablation and bulk
ultrasound thermal ablation.
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Chapter III
Conclusions
3.1 Summary
An unmet need of thermal ablation is real time mapping of heat–induced cell death
(Li et al., 2014). To this end, echo decorrelation imaging is currently being studied as a
ultrasound–based method for real time thermal ablation guidance and monitoring.
The central hypothesis of this study was that ultrasound echo decorrelation accurately
predicts in vivo ultrasound thermal ablation. To test this hypothesis, in vivo pulse–echo
imaging of high–intensity focused ultrasound (HIFU) and bulk ultrasound thermal abla-
tion were performed on rabbit liver and VX2 tumor. The prediction performance of echo
decorrelation and integrated backscatter (IBS) was determined by comparing the parameter
maps to triphenyl tetrazolium chloride (TTC) stained histology and computing the receiver
operating characteristic (ROC) curve.
The central hypothesis of this study was confirmed for focused exposures, unfocused
exposures, and all exposures combined, in both normal liver and VX2 tumor for echo decor-
relation. For the focused exposures, unfocused exposures, and all exposures combined, ab-
lated normal liver was predicted significantly better by echo decorrelation than IBS. For the
focused exposures, unfocused exposures, and all exposures combined, ablated VX2 tumor
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was not predicted significantly better by echo decorrelation in comparison to IBS. Anal-
ysis of inter–frame time effects illustrated a marginally significant decrease in prediction
performance by echo decorrelation for large tissue motion.
These results suggest that echo decorrelation imaging merits further investigation and
has potential to improve liver cancer ablation outcomes. In addition to liver cancer thermal
ablation, echo decorrelation imaging could also improve outcomes for other emerging ther-
mal ablation cancer therapies for breast tumors, pancreatic cancer, kidney tumors, thyroid
and parathyroid tumors (Maloney et al., 2015). Ultrasound guided HIFU (USgHIFU) and
magnetic resonance imaging guided HIFU (MRgHIFU) systems have been used to safely
guide HIFU therapy for these soft tissue cancers (Maloney et al., 2015). The deployment of
these imaging technologies indicates a need for real time image monitoring, for which echo
decorrelation imaging could provide a relatively low cost and less complex solution.
Echo decorrelation imaging could also improve outcomes for emerging non–cancer ther-
mal ablation therapies. These include thermal therapies for the heart (e.g., atrial fibril-
lation, ventricular tachycardia, and transmyocardial revascularization therapies) (O’Reilly
et al., 2015; Salgaonkar et al., 2015) and thermal sympathetic nerve modulation for hyperten-
sion (Shetty et al., 2015). ProRhythm (Ronkonkoma, NY), formerly Transurgical, (Schmidt
et al, 2007) and Atrionix Inc. (Natale et al., 2000) have developed transballoon ultrasound
ablation catheters for atrial fibrillation therapy and both saw positive results in initial hu-
man studies. Symplicity (Medtronic, Palo Alto, CA, USA), the Therapeutic Intra Vascular
Ultrasound (TIVUS) System developed by Cadriosonic Ltd (Tel Aviv, Israel) and the PAR-
ADISE (ReCor Medical, Ronkonkoma, NY, USA) system, which has received the CE–mark,
have been developed for thermal sympathetic nerve modulation (Shetty et al., 2015). The
TIVUS and PARADIS systems leverage non–focused ultrasound thermal ablation (i.e., bulk
ultrasound thermal ablation) approaches (Shetty et al., 2015) where as Symplicity leverages
radiofrequency energy (Shetty et al., 2015). Ablation efficacy could be improved by deploy-
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ing echo decorrelation imaging. Currently, these approaches do not have methods to monitor
ablation directly (Shetty et al., 2015; O’Reilly et al., 2015; Salgaonkar et al., 2015).
3.2 Future directions
An important next step is assessing echo decorrelation ability to successfully control ab-
lation in real time. Control by echo decorrelation would be assessed in a series of in vitro
studies where corrected echo decorrelation images would be computed in real time from
pulse–echo images of in vitro HIFU and bulk ultrasound ablation in bovine liver. Treatment
could be terminated when the local mean or maximum log10–scaled echo decorrelation any-
where within the planned treatment zone reaches an optimal threshold. The threshold for
ablation control should be designed to achieve at least a specificity of 90%, thus potentially
decreasing the odds of local recurrence; however, the cost will be lower sensitivity. To achieve
a 90% specificity, Figure 2.19 indicates the optimal threshold for ablated liver and VX2 tu-
mor prediction by log10–scaled echo decorrelation would be −2.9 and −2.3 respectively. The
sensitivities at these thresholds would be 0.65 and 0.43 for ablated liver and VX2 tumor
prediction. Preliminary verifications would demonstrate total treatment zone ablation after
therapy termination. After initial verification in vitro, additional in vivo studies would be
conducted to assess in vivo HIFU and bulk ultrasound ablation control.
An additionally important next step is translation of real time ultrasound echo decorre-
lation imaging monitoring into clinical radiofrequency ablation (RFA) to assess echo decor-
relation’s ablation prediction performance in realistic liver tissue (e.g., inflamed, cirrhotic,
and fatty infiltrated liver).
Echo decorrelation imaging is expected to successfully predict thermal ablation in a clini-
cal setting, as echo decorrelation is believed to map thermal–induced tissue micro–structural
changes as well as transient gas activity (Hooi et al., 2015). These micro–structural changes
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are believed to be due to cellular swelling, microvascular changes, protein denaturation,
and microstructural tissue damage due to water vaporization during thermal ablation (Gra-
vante et al., 2011). These processes can involve changes in proteins, which serve as the
structural molecule of all cells (O’Connor et al., 2010), or water vaporization. Additionally,
microstructural changes of saturated fatty acids are expected at their approximate melting
temperature (43–69 ◦C) (Timberlake et al., 2014). As liver tissues are primarily composed
of these molecules, echo decorrelation imaging is hypothesized to predict thermal ablation
even in the presence of liver tissue abnormalities like inflammation, liver cirrhosis, and fatty
infiltrations.
Echo decorrelation images could be computed from pulse–echo images acquired during
clinical RFA and compared to follow–up CT images (computed tomography), MR (magnetic
resonance) images, post–surgical biopsies, or simulated RFA lesions to assess echo decorre-
lation’s ablation prediction performance during abnormal liver ablation. Ultrasound probe
position sensors would allow accurate registration of echo decorrelation images with a surro-
gate tissue ablation map, as done by Mauri et al. (2015) for B–mode (brightness mode) and
CT/MRI registration.
Echo decorrelation could be computed from two–dimensional pulse–echo images for ex-
perimental simplicity. However, volume (i.e., three–dimensional) ultrasound imaging tech-
nologies could be leveraged for enhanced monitoring as thermal ablation is intrinsically
three–dimensional. Volume ultrasound imaging has previously been deployed for liver tumor
targeting and RFA treatment planning (i.e., tumor dimensioning, RFA needle selection, and
needle placement) and was found superior to two–dimensional ultrasound imaging (Kunzli
et al., 2011). Ablated zones mapped by echo decorrelation imaging would further enhance
treatment planning such as RFA needle electrode selection and the placement of a single
or a combination of electrodes (Kunzli et al., 2011). These procedural advancements could
increase the ablated zone diameters to as large as 7 cm (Kunzli et al., 2011). Enhanced
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planning would overall result in lower local recurrence rates for both smaller tumors (2 to 3
cm in diameter; recurrence rate 21.6%) and larger tumors (>3 cm in diameter; recurrence
rate 52.8%; (Kunzli et al., 2011).
These important next steps would demonstrate echo decorrelation imaging’s clinical
translatability and efficacy in monitoring thermal ablation of liver and other soft tissue
cancers (e.g., breast tumors, pancreatic cancer, kidney tumors, thyroid and parathyroid
tumors). Efficacy of non–cancer therapies such as treatments for the heart (e.g., atrial fib-
rillation, ventricular tachycardia, and transmyocardial revascularization therapies) and ther-
mal sympathetic nerve modulation for hypertension could also be improved by this novel
ultrasound–based approach.
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Chapter IV
Appendix
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Trial # Rabbit On time Off time Cycles A.P.O. Voltage Energy Abs. Fdepth Aperture Pgain ISPTP
ID # (s) (s) (W) (V) (J) (mm) (W/cm2)
Date: 1/27/2014 Array: THX5A JV815 fc: 5.00 MHz
1 R252 / Middle lobe 7.5 5.5 6 39 14.70 1755 ∞ 1-64 1.43 68
2 R252 / Right lobe 7.5 5.5 6 24 10.56 1080 ∞ 1-64 1.43 42
3 R252 / Left lobe 7.5 5.5 6 32 12.70 1440 ∞ 1-64 1.43 56
1 R253 / Left lobe 1 5 6 25 10.70 150 36.00 1-64 4.86 505
2 R253 / Middle lobe 1 5 6 21 8.86 126 36.00 1-64 4.86 424
3 R253 / Right lobe 1 5 6 25 10.70 150 36.00 1-64 4.86 505
Date: 4/29/2014 Array: THX5A SN004 fc: 5.20 MHz
1 R256 / Right lobe 1 5 6 22 9.23 132 30.00 1-64 6.52 800
2 R256 / Middle lobe 1 5 6 26 10.21 156 30.00 1-64 6.52 945
N3 R256 / Left lobe 7.5 5 6 35 12.49 1575 ∞ 100 1.44 50
O4 R259 / Right lobe 7.5 5 6 28 10.70 1260 ∞ 100 1.44 62
5 R259 / Middle lobe 1 5 6 30 11.15 180 30.00 1-64 6.52 1091
6 R259 / Middle lobe 1 5 6 30 11.50 180 30.00 1-64 6.52 1091
7 R259 / Left lobe 1 5 6 35.4 12.50 212 30.00 1-64 6.52 1287
8 R259 / Left lobe 1 5 6 35.4 12.50 212 30.00 1-64 6.52 1287
Date: 7/2/2014 Array: THX5A SN003 fc: 5.05 MHz
1 R265 / Left lobe 6 2.5 9 25 10.70 1350 ∞ 1-32 1.45 45
2 R265 / Middle lobe 6 2.5 9 29.17 11.80 1575 ∞ 1-32 1.45 52
3 R265 / Right lobe 6 2.5 7 33.03 13.00 1387 ∞ 1-32 1.45 59
4 R266 / Left lobe 0.7 3.3 9 28.6 11.60 180 30.00 1-64 6.58 1057
5 R266 / Middle lobe 0.7 3.3 9 23.8 10.50 150 30.00 1-64 6.58 880
A6 R266 / Right lobe 0.7 3.3 9 23.8 10.50 150 27.00 1-64 7.29 1080
Date: 11/17/2014 Array: THX5A SN007 fc: 5.00 MHz
P 1 R267 / Left lobe 6 2.5 9 30 12.00 1620 ∞ 1-64 1.43 52
B2 R267 / Middle lobe 0.7 3.3 9 24 10.50 151 25.00 1-64 7.64 1196
3 R267 / Right lobe 0.7 3.3 9 28 11.50 176.40 27 1-64 7.34 1287
C4 R267 / Right lobe 0.7 3.3 9 28 11.50 176 28.00 1-64 7.14 1220
D5 R268 / Left lobe 0.7 3.3 9 28 11.50 176 26.00 1-64 7.51 1351
6 R268 / Right lobe 6 2.5 9 30 12.00 1620 ∞ 1-64 1.43 52
E7 R268 / Middle lobe 0.7 3.3 9 24 10.50 151 27.00 1-64 7.34 1103
F 8 R268 / Middle lobe 0.7 3.3 9 24 10.50 151 25.00 1-64 7.64 1196
Table 4.1: Exposures for all in vivo experiments. Superscript letters denote trials analyzed in this thesis (Figures 2.5).
For each experiment day, the linear image-ablate array identification number and center frequency are listed. For each
trial, the rabbit identification number, liver lobe, sonication time, rest time, number of sonication pulses, acoustic power
output (APO) and its calibrated voltage, total energy absorbed, electronic focal depth, the percent of the available active
aperture used, pressure gain determined from simulations (Mast et al., 2007), and spatial peak-temporal peak in situ
intensity are listed.
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Trial # Rabbit On time Off time Cycles A.P.O. Voltage Energy Fdepth Aperture Pgain ISPTP
ID # (s) (s) (W) (V) (J) (mm) (W/cm2)
Date: 12/17/2014 Array: THX5A SN007 fc: 5.00 MHz
1 R269 / Left lobe 0.7 2.8 9 28 11.50 176 ∞ 1-64 1.43 47
Q2 R269 / Middle lobe 6 2.5 9 35 13.12 1890 ∞ 100 1.43 61
3 R269 / Right lobe 0.7 2.8 9 24 10.36 151 ∞ 1-64 1.43 42
3 (left mark) R269 / Right lobe 6.5 2.5 7 34 13.00 1547 ∞ 1-10 1.43 59
3 (right mark) R269 / Right lobe 6.5 2.5 6 34 13.00 1326 ∞ 55-64 1.43 59
R4 R270 / Left lobe 6 2.5 9 30 11.72 1620 ∞ 1-64 1.43 52
5 R270 / Middle lobe 0.7 2.8 9 28 11.50 176 ∞ 1-64 1.43 49
5 (left mark) R270 / Middle lobe 6.5 2.5 10 34 13.00 2210 ∞ 1-10 1.43 59
5 (right mark) R270 / Middle lobe 6.5 2.5 9 34 13.00 1989 ∞ 55-64 1.43 59
S6 R270 / Right lobe 6 2.5 8 35 13.12 1680 ∞ 1-64 1.43 61
7 R270 / Right lobe 0.7 3.3 9 28 11.50 176 ∞ 1-64 1.43 59
8 R270 / Left lobe 0.7 3.3 9 28 11.50 176 ∞ 1-64 1.43 59
Date: 2/4/2015 Array: THX5A SN913 fc: 5.40 MHz
T 1 R271 / Middle lobe 6 2.5 9 30 13.20 1620 ∞ 1-64 1.45 54
G2 R271 / Left lobe 0.7 2.8 9 24 11.24 151 24.00 1-64 7.10 1033
2 (left mark) R271 / Left lobe 6 2.5 5 33 14.00 990 ∞ 1-10 1.45 59
2 (right mark) R271 / Left lobe 6 2.5 3 33 14.00 594 ∞ 55-64 1.45 59
3 R271 / Right lobe 0.7 2.8 9 20 10.06 126 26.00 1-64 7.30 911
H4 R272 / Left lobe 0.7 2.8 9 28 12.50 176 23.00 1-64 6.66 1061
4 (left mark) R272 / Left lobe 6 2.5 6 33 14.00 1188 ∞ 1-10 1.45 59
4 (right mark) R272 / Left lobe 6 2.5 10 33 14.00 1980 ∞ 55-64 1.45 59
I5 R272 / Middle lobe 0.7 2.8 9 20 10.06 126 26.00 1-64 7.30 911
J6 R272 / Right lobe 0.7 2.8 9 24 11.24 151 24.00 1-64 7.10 1033
K7 R272 / Left lobe 0.7 3.3 9 24 11.24 151 24.00 1-64 7.10 1033
Date: 3/23/2015 Array: THX5A SN913 fc: 5.40 MHz
U1 R273 / Middle lobe 6 2.5 7 35 14.00 1470 ∞ 1-64 1.45 63
2 R273 / Left lobe 0.7 2.8 6 28 12.51 118 25.00 1-64 7.35 1292
2 (left mark) R273 / Left lobe 6 2.5 10 33 14.00 1980 ∞ 1-10 1.45 59
2 (right mark) R273 / Left lobe 6 2.5 6 33 14.00 1980 ∞ 55-64 1.45 59
L3 R273 / Right lobe 0.7 2.8 6 24 11.24 101 25.00 1-64 7.35 1107
3 (left mark) R273 / Right lobe 6 2.5 5 33 14.00 990 ∞ 1-10 1.45 59
3 (right mark) R273 / Right lobe 6 2.5 10 33 14.00 1980 ∞ 55-64 1.45 59
V 1 R274 / Left lobe 6 2.5 8 30 13.12 1440 ∞ 1-64 1.45 54
W 2 R274 / Middle lobe 6 2.5 9 35 14.00 1890 ∞ 1-64 1.45 63
M3 R274 / Right lobe 0.7 2.8 9 28 12.15 176 25.00 1-64 7.35 1292
3 (left mark) R274 / Right lobe 6 2.5 4 33 14.00 792 ∞ 1-10 1.45 59
3 (right mark) R274 / Left lobe 6 2.5 10 33 14.00 1980 ∞ 55-64 1.45 59
Table 4.1 continued.
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Trial # Iris B–scan before thx Iris B–scan after thx Filename (sham) Filename (thx) Max. tumor dia.
Date: 1/27/2014 Array: THX5A JV815 fc: 5.00 MHz
1 12:11:31 12:11:05 NA NA no tumor
2 12:31:39 12:31:28 NA 01272014 111619 6.0
3 12:41:44 12:48:32 01272014 112813 01272014 113014 no tumor
1 12:41:44 12:48:24 01272014 125927 01272014 130111 no tumor
2 2:15:13 2:18:27 01272014 132311 01272014 132517 no tumor
3 2:59:47 3:05:44 01272014 133915 01272014 134446 3.1
Date: 4/29/2014 Array: THX5A SN004 fc: 5.20 MHz
1 8:59:00 9:03:00 04292014 185927 04292014 090142 11.5
2 9:10:00 9:14:00 04292014 091019 04292014 091305 no tumor
N3 9:25:00 9:36:00 04292014 092757 04292014 093434 11.0
O4 10:50:00 11:05:00 04292014 105943 04292014 110305 11.1
5 11:26:00 11:33:00 04292014 112810 04292014 113148 13.6
6 11:40:00 11:43:00 04292014 114050 04292014 114220 no tumor
7 11:50 11:54 04292014 115020 04292014 115311 9.2
8 11:59 12:03 04292014 120000 04292014 120140 no tumor
Date: 7/2/2014 Array: THX5A SN003 fc: 5.05 MHz
1 8:46:00 8:52:00 07022014 084549 07022014 084853 no tumor
2 9:15:00 9:20:00 07022014 091429 07022014 091710 no tumor
3 9:32:00 9:42:00 07022014 093410 07022014 093706 tumor
4 11:27:00 11:33:00 07022014 112942 07022014 113112 no tumor
5 11:48:00 12:07:00 07022014 114739 07022014 115307 no tumor
A6 12:18:00 12:26:00 07022014 122208 07022014 122407 no tumor
Date: 11/17/2014 Array: THX5A SN007 fc: 5.00 MHz
P 1 8:11:00 8:19:00 11172014 092824 11172014 092824 5.1
B2 8:34:00 8:35:00 11172014 094831 11172014 094831 6.0
3 8:49:00 8:52:00 11172014 100331 11172014 100331 7.8
C4 9:01:00 9:04:00 11172014 101503 11172014 101503 no tumor
D5 10:10:00 10:15:00 11172014 112547 11172014 112547 5.4
6 10:29:00 10:33:00 11172014 114239 11172014 114239 10.6
E7 10:38 10:40 11172014 115127 11172014 115127 no tumor
F 8 10:43 10:46 11172014 115719 11172014 115719 no tumor
Table 4.2: Time stamps of B–scans taken with the Iris system before and after treatment,
the raw pulse-echo data filename, and effective tumor diameters were recorded for each
experiment.
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Trial # Iris B–scan before thx Iris B–scan after thx Filename (sham) Filename (thx) Max. tumor dia.
Date: 12/17/2014 Array: THX5A SN007 fc: 5.00 MHz
1 7:28:00 7:27:00 12172014 084053 12172014 084053 no tumor
Q2 7:52:00 7:55:00 12172014 090453 12172014 090453 10.1
3 8:06:00 8:08:00 12172014 091846 12172014 091846 no tumor
3 (left mark) NA 8:13:00 12172014 092247 12172014 092247 NA
3 (right mark) NA 8:19:00 12172014 092812 12172014 092812 NA
R4 9:12:00 9:16:00 12172014 102531 12172014 102531 3.5
5 9:22:00 9:25:00 12172014 103634 12172014 103634 no tumor
5 (left mark) NA 9:30:00 12172014 103855 12172014 103855 NA
5 (right mark) NA 9:33:00 20141217 104310 20141217 104310 NA
S6 9:49:00 9:53:00 12172014 110242 12172014 110242 5.3
7 9:59 10:03 12172014 111425 12172014 111425 no tumor
8 10:16 10:19 12172014 112937 12172014 112937 no tumor
Date: 2/4/2015 Array: THX5A SN913 fc: 5.40 MHz
T 1 8:47:00 8:54:00 02042015 084822 02042015 084822 3.5
G2 9:09:00 9:14:00 02042015 091009 02042015 091009 7.7
2 (left mark) NA 9:22:00 02042015 091555 02042015 091555 NA
2 (right mark) NA 9:28:00 02042015 092217 02042015 092217 NA
3 9:38:00 9:41:00 02042015 093710 20402015 093710 no tumor
H4 11:01:00 11:07:00 02042015 110338 02042015 110338 8.1
4 (left mark) NA 11:12:00 02042015 110642 02042015 110642 NA
4 (right mark) NA 11:16:00 02042015 111012 02042015 111012 NA
I5 11:29:00 11:32:00 02042015 112841 02042015 112841 no tumor
J6 11:46:00 11:48:00 02042015 114410 02042015 114410 no tumor
K7 11:58 12:00 02042015 115645 02042015 115645 no tumor
Date: 3/23/2015 Array: THX5A SN913 fc: 5.40 MHz
U1 7:35:00 7:42:00 03232015 083552 03232015 083552 no tumor
2 7:52:00 7:57:00 03232015 085211 03232015 085211 12.0
2 (left mark) 7:58:00 8:01:00 20150323 090728 20150323 090728 NA
2 (right mark) 8:01:00 8:18:00 NA NA NA
L3 8:34 8:38:00 03232015 093232 03232015 093232 9.8
3 (left mark) NA 8:44:00 03232015 093722 03232015 093722 NA
3 (right mark) 8:44 8:48:00 03232015 094144 03232015 094144 NA
V 1 10:13:00 10:17:00 03232015 111056 03232015 111056 no tumor
W 2 10:30:00 10:33:00 03232015 112703 03232015 112703 8.5
M3 10:40:00 11:43:00 03232015 113758 03232015 113758 14.4
3 (left mark) NA 10:47 03232015 114042 03232015 114042 NA
3 (right mark) 10:47 11:47 03232015 114417 03232015 114417 NA
Table 4.2 continued.
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